enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada. Show more

Location: 4868 Rue Levy, Montreal, QC, H4R 2P1, Canada | Website: https://www.engene.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

396.7M

52 Wk Range

$2.65 - $11.00

Previous Close

$7.75

Open

$7.68

Volume

65,778

Day Range

$7.19 - $7.81

Enterprise Value

246.2M

Cash

201.9M

Avg Qtr Burn

-23.46M

Insider Ownership

13.60%

Institutional Own.

89.58%

Qtr Updated

07/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.